T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated

[News]

Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

More... (https://www.news-medical.net/news/20221207/T-DXd-shows-high-efficacy-in-HER2-positive-breast-cancer-patients-previously-treated-with-T-DM1.aspx)